MEDIPOST Co., Ltd.
Financials
Valuation Metrics
MEDIPOST Co., Ltd.'s Market Cap is ₩3262B. At end of 2025 it was ₩7131B. Ranked #592 of 2,405 in KR market (top 25%), #239 of 1,627 on KOSDAQ (top 15%), #17 of 94 in Health Care Equipment & Services (top 18%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 326.18B KRW | KR#592/2,405 Sec#17/94 |
| Revenue | 74.84B KRW | KR#1,581/2,405 Sec#44/94 |
| Net Income | -23.72B KRW | KR—/2,405 Sec—/94 |
| Total Assets | 558.88B KRW | KR#720/2,405 Sec#11/94 |
| Net Assets | 273.68B KRW | KR#766/2,405 Sec#17/94 |
| Employees | 648 | KR#387/2,405 Sec#5/94 |
| Value | ||
| P/B | 1.19x | KR#1,675/2,405 Sec#54/94 |
| P/S | 4.36x | KR#2,123/2,405 Sec#71/94 |
| FCF Yield | -18.41% | KR—/2,405 Sec—/94 |
| Profitability | ||
| ROE | -8.67% | KR#1,903/2,405 Sec#64/94 |
| ROA | -4.24% | KR#1,894/2,405 Sec#63/94 |
| Op. Margin | -102.23% | KR#2,286/2,405 Sec#84/94 |
| Revenue Growth | 3.70% | KR#1,274/2,405 Sec#65/94 |
| Financial Health | ||
| Debt Ratio | 104.21% | KR#1,589/2,405 Sec#81/94 |
| Total Debt | 158.44B KRW | KR#588/2,405 Sec#9/94 |
| FCF | -60.06B KRW | KR#2,086/2,405 Sec#81/94 |
| Cash | 78.36B KRW | KR#557/2,405 Sec#8/94 |
| Current Ratio | 1.27x | KR#1,418/2,405 Sec#72/94 |
| Performance | ||
| 1Y Return | -51.88% | KR#1,988/2,405 Sec#75/94 |
| 1M Return | -14.32% | KR#1,523/2,405 Sec#60/94 |
| From 52W High | -71.41% | KR#2,096/2,405 Sec#79/94 |
| 1Y MDD | -73.14% | KR#2,087/2,405 Sec#79/94 |
| Trading | ||
| Volume | 28,414 shares | KR#1,314/2,405 Sec#49/94 |
| Trading Value | 236.0M KRW | KR#1,062/2,405 Sec#38/94 |
| Foreign Own. | 2.32% | KR#1,509/2,405 Sec#53/94 |
| Per Share | ||
| EPS | -605 KRW | KR—/2,405 Sec—/94 |
| BPS | 6,981 KRW | KR#1,255/2,405 Sec#29/94 |
Company Info
Medipost, established in 2000 and listed on KOSDAQ in 2005, specializes in umbilical cord blood banking and stem cell therapy development. The company operates an umbilical cord blood bank, sells the degenerative arthritis treatment Cartistem, and develops umbilical cord blood-derived stem cell therapies. It also engages in the health functional food business, offering multivitamins and probiotics. Medipost is headquartered in Seongnam-si, Gyeonggi-do, and actively expands its market reach through awareness campaigns, global clinical trials for Cartistem, and diversified online marketing channels.